Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.
Samuel T. Wilkinson, Sandhya Prashad, Rachel Dalthorp, Lisa Harding, Brandon Kitay, Sagar V Parikh, James Dziura, Ashley Clayton, Geena Fram, Valerie Lepoutre, Julianna Brown, Robert Ostroff, Gerard Sanacora
Contemp Clin Trials March 2, 2026 DOI: 10.1016/j.cct.2026.108273 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Non-inferiority, comparative effectiveness study Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Interventions | Intravenous ketamine Intranasal esketamine |
| Topics | Depression Esketamine Ketamine |
| Citations | 1 |
| Key points | The protocol describes a planned non-inferiority trial comparing intranasal esketamine to intravenous ketamine for treatment-resistant depression. |
Abstract
Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.